Yu Evan Y, Mankoff David A
Seattle Cancer Care Alliance, Division of Medical Oncology, 825 Eastlake Avenue East, G4-836, Seattle, WA 98109, USA.
Expert Rev Mol Diagn. 2007 Sep;7(5):659-72. doi: 10.1586/14737159.7.5.659.
The practice of oncology is changing, with novel biologic agents broadening our therapeutic armamentarium. Along with excitement and promise, multiple new challenges arise. The concept of 'individualized cancer care,' where therapies are selected based on the unique characteristics of a patient's tumor, is gaining favor as an approach to address the heterogeneity of cancer. As a result, we must strive to discover biomarkers with prognostic and predictive value to improve drug selection, alteration and development. Metabolic and molecular imaging with PET appears at the forefront of this critical field. In this review, we discuss cancer biomarker development, opportunities for PET to elucidate tumor biology and the potential role of PET in clinical research and practice.
肿瘤学实践正在发生变化，新型生物制剂拓宽了我们的治疗手段。在带来兴奋和希望的同时，也出现了诸多新挑战。“个体化癌症治疗”的概念，即根据患者肿瘤的独特特征选择治疗方法，作为应对癌症异质性的一种方法正日益受到青睐。因此，我们必须努力发现具有预后和预测价值的生物标志物，以改善药物选择、调整和研发。正电子发射断层显像（PET）的代谢和分子成像似乎处于这一关键领域的前沿。在本综述中，我们讨论了癌症生物标志物的研发、PET阐明肿瘤生物学的机会以及PET在临床研究和实践中的潜在作用。
